Is ABT Stock a Good Investment?
Abbott Laboratories, traded on the New York Stock Exchange under the ticker ABT, is not the kind of company that depends on a single medicine or product. Its business stretches across medical devices, diagnostic testing, nutritional products, and established pharmaceutical products sold primarily outside the United States. This diversification is one of the main reasons investors often view ABT as a relatively defensive healthcare stock. (Abbott)
At the latest market close available, ABT traded at approximately $100.68 per share, with a market value of roughly $175.9 billion. Its trailing price-to-earnings ratio was about 28.2, meaning the stock was not priced like a deeply discounted company. Investors appeared to be paying a premium for Abbott’s established brands, recurring healthcare demand and potential growth in medical technology.
What Does Abbott Laboratories Actually Do?
Abbott is a global healthcare company whose operations are divided into four major areas:
- Medical devices
- Diagnostic products
- Nutritional products
- Established pharmaceutical products
Its medical-device portfolio includes products for diabetes care, cardiovascular treatment, heart monitoring and pain management. Abbott also sells laboratory and point-of-care diagnostic systems, including the Afinion, i-STAT and ID NOW platforms. Its nutrition division owns widely recognized brands such as Ensure, Similac, PediaSure, Pedialyte and Glucerna. (SEC)
This matters to investors because Abbott is not completely dependent on the success of one blockbuster drug. Weakness in one business can sometimes be balanced by stronger performance in another.
FreeStyle Libre Is One of Abbott’s Most Important Growth Products
One of Abbott’s most valuable businesses is diabetes care, particularly the FreeStyle Libre continuous glucose-monitoring system. The system allows users to monitor glucose levels with a wearable sensor rather than relying only on traditional finger-stick testing.
Continuous glucose monitoring has become an important growth area because diabetes is a long-term condition that requires regular management. Abbott benefits not only from selling the initial system but also from the recurring demand for replacement sensors.
The opportunity extends beyond people who already use insulin. Abbott has also been developing consumer-facing glucose technology, although the company clearly states that products such as Lingo are not intended to diagnose disease and are not guaranteed to produce the same results for every user.
For ABT shareholders, the key point is simple: FreeStyle Libre gives Abbott exposure to a large healthcare market with recurring purchases and long-term demand.
Abbott’s Recent Financial Performance
Abbott reported $44.3 billion in sales for 2025, representing reported growth of 5.7%. Excluding COVID-19 testing-related effects, its underlying base business generated organic sales growth of 6.7%. Growth was led mainly by Medical Devices and Established Pharmaceutical Products. (Abbott)
During the first quarter of 2026, Abbott reported:
- Sales of approximately $11.2 billion
- Reported sales growth of 7.8%
- Comparable sales growth of 3.7%
- Adjusted diluted earnings per share of $1.15
- GAAP diluted earnings per share of $0.61 (Abbott)
These results show that Abbott is still growing, although growth is not perfectly even across every quarter or business division. Investors should therefore pay attention not only to headline revenue but also to organic growth, operating margins and performance within the medical-device segment.
Why Investors Like ABT Stock
1. A diversified healthcare business
Abbott earns revenue from devices, diagnostics, nutrition and pharmaceuticals. That gives the company more balance than a healthcare business built around one product category. (SEC)
2. Exposure to long-term healthcare demand
Demand for diabetes management, cardiovascular products, diagnostic testing and nutritional support is unlikely to disappear. Abbott’s products are connected to ongoing medical needs rather than short-lived consumer trends.
3. Strong recognizable brands
Brands such as FreeStyle Libre, Ensure, Similac and Pedialyte are familiar to patients, families and healthcare professionals. Strong brand recognition can help protect market position, although it does not eliminate competition.
4. A long history of dividend payments
Abbott has paid quarterly dividends since 1924 and had increased its annual dividend for more than 50 consecutive years by 2022. This history has placed the company among the S&P 500 Dividend Aristocrats, a group of companies known for long records of dividend growth. (Abbott)
A long dividend history does not guarantee future increases, but it does demonstrate that returning cash to shareholders has been an important part of Abbott’s capital-allocation approach.
5. Continued investment in new healthcare technology
Abbott continues to develop products in continuous glucose monitoring, cardiovascular care, rapid diagnostics and biowearables. Its broad product portfolio includes pacemakers, heart-valve therapies, cardiac monitors, stents and laboratory systems. (Abbott)
The Main Risks of Buying ABT Stock
ABT may be a high-quality company, but that does not mean the stock is risk-free.
Valuation risk
With a price-to-earnings ratio of approximately 28 at the latest market close, ABT was trading at a valuation that already reflected expectations for future growth. When investors pay a high multiple, even respectable financial results can cause the share price to fall if they are weaker than expected.
Product competition
Abbott competes with large medical-technology, diagnostics, nutrition and pharmaceutical companies. In diabetes technology, it must continue improving FreeStyle Libre while facing competing continuous glucose-monitoring systems.
Regulation and product safety
Medical products must meet strict regulatory and quality requirements. Product recalls, manufacturing problems, delayed approvals or unexpected safety issues can damage sales and investor confidence.
Currency and international-market exposure
Abbott operates internationally, so exchange-rate movements can affect reported revenue and earnings. Economic instability, changing regulations and pricing pressure in foreign markets may also influence results.
Uneven diagnostic demand
Abbott benefited significantly from COVID-19 testing during the pandemic. As that demand declined, investors had to distinguish between temporary testing revenue and growth in Abbott’s underlying businesses. The company now frequently reports results with and without COVID-19 testing effects to make that comparison clearer. (Abbott)
Is ABT Stock a Buy?
ABT appears more suitable for investors seeking a combination of healthcare growth, business stability and dividend history than for people searching for a very cheap stock or a rapid speculative gain.
The strongest argument for owning Abbott is the quality of the underlying business. The company sells products that patients and healthcare systems repeatedly need. FreeStyle Libre provides a meaningful growth engine, while nutrition, diagnostics, cardiovascular devices and pharmaceuticals create additional sources of revenue.
The main concern is price. A strong company can still be a poor investment when purchased at an excessively high valuation. ABT’s valuation suggests that the market already expects continued earnings growth. Investors should therefore compare the current price with Abbott’s expected earnings, cash flow, dividend yield, and long-term growth before purchasing shares.
A sensible approach may be to place ABT on a watchlist, review its next quarterly earnings announcement and consider buying gradually rather than investing an entire amount at one price. Abbott normally releases earnings in January, April, July and October. (Abbott)
Final View
Abbott Laboratories is a real, profitable and diversified healthcare company with respected brands and a long operating history. Its future growth is likely to depend heavily on medical devices, particularly diabetes and cardiovascular technology, while nutrition, diagnostics and international pharmaceuticals provide stability.
ABT stock may appeal to long-term investors who value dependable healthcare demand and dividend growth. However, its relatively high valuation means that buyers should not ignore execution risks, competition or the possibility of a lower share price.
ABT is best viewed as a quality company that still needs to be purchased at a sensible price, not as a guaranteed winning investment.
Five Best Pictures for This Article
- FreeStyle Libre glucose monitor — Place beside the section discussing Abbott’s diabetes-care growth.
- Abbott Afinion or i-STAT diagnostic machine — Use in the company business overview.
- Ensure, Similac, PediaSure, and Pedialyte product collection — Add to the nutrition-business section.
- Abbott ID NOW diagnostic system — Use in the risks or diagnostics discussion.
- ABT historical stock-price chart — Place after the current price and valuation paragraph.
